SART1 Antibody

Product Discontinued

SART1 Antibody Summary

• Immunogen: Peptide with sequence GSSKKHRGEKEAA-C corresponding to N-Terminus according to NP_005137.1.
• Localization: Cytoplasmic and Nuclear
• Specificity: This antibody is expected to recognise both the human SART1(800) and SART1(259) proteins.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: SART1
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Peptide ELISA Detection limit 1:64000
  • Western Blot 0.03 - 0.1 ug/ml
• Application Notes: WB: Approx. 125 kDa band observed in HeLa lysates (calculated MW of 90.3 kDa band according to NP_005137) and is in agreement with scientific literature (Vertegaal et al).
• Control:

  HeLa Whole Cell Lysate

Reactivity Notes

Predicted cross-reactivity based on sequence identity: Mouse, Rat, Bovine.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris (pH 7.3), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for SART1 Antibody

• Allergen Hom s 1
• Ara1
• HAF
• HOMS1
• hSART-1
• hSnu66
• hypoxia-associated factor
• IgE Autoantigen
• MGC2038
• SART1
• SART-1
• SART1(259) protein
• SART1(800) protein
• SART1259
• small nuclear ribonucleoprotein 110kDa (U4/U6.U5)
• SNRNP110
• SNU66 homolog
• Snu66
• squamous cell carcinoma antigen recognised by T cells
• Squamous cell carcinoma antigen recognized by T cells 1
• squamous cell carcinoma antigen recognized by T cells
• U4/U6.U5 tri-snRNP-associated 110 kDa protein
• U4/U6.U5 tri-snRNP-associated protein 1

Background

SART1 encodes two proteins, the SART1(800) protein expressed in the nucleus of the majority of proliferating cells, and the SART1(259) protein expressed in the cytosol of epithelial cancers. The SART1(259) protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1(259) protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1(259) antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1(259) protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SART1 Antibody (NB100-1145)(1)

Publication using NB100-1145

• Vertegaal AC, Ogg SC, Jaffray E et al. A proteomic study of SUMO-2 target proteins. J Biol Chem 2004-08-06 [PMID: 15175327]

Bioinformatics

• Gene Symbol: SART1
• Entrez:
  • 9092(Human)
  • 20227(Mouse)
  • 29678(Rat)
• Uniprot:
  • NP_005137.(Human)